ZBIO

Zenas Biopharma Inc

Sep 17 • 04:00PM ET

19.07

+0.83 4.52 %

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM IWN VXF VTWO SCHA FESM IWC SBIO VTWV

Index	RUT	P/E	-	EPS (ttm)	-4.23	Insider Own	75.52%	Shs Outstand	42.09M	Perf Week	-3.66%
Market Cap	802.83M	Forward P/E	-	EPS next Y	-4.33	Insider Trans	0.00%	Shs Float	10.31M	Perf Month	10.33%
Enterprise Value	530.56M	PEG	-	EPS next Q	-0.67	Inst Own	35.90%	Short Float	55.87%	Perf Quarter	96.95%
Income	-177.01M	P/S	53.52	EPS this Y	71.19%	Inst Trans	11.90%	Short Ratio	30.12	Perf Half Y	141.33%
Sales	15.00M	P/B	3.35	EPS next Y	-26.53%	ROA	-71.80%	Short Interest	5.76M	Perf YTD	132.78%
Book/sh	5.69	P/C	2.94	EPS next 5Y	32.56%	ROE	-88.40%	52W High	26.25 -27.37%	Perf Year	5.04%
Cash/sh	6.49	P/FCF	-	EPS past 3/5Y	-9.85% -	ROIC	-73.80%	52W Low	5.83 227.02%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	99.31%	Volatility	11.47% 9.16%	Perf 5Y	-
Dividend TTM	-	EV/Sales	35.37	EPS Y/Y TTM	-	Oper. Margin	-1260.67%	ATR (14)	1.68	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.23	Sales Y/Y TTM	-	Profit Margin	-1180.04%	RSI (14)	53.80	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.23	EPS Q/Q	-25.86%	SMA20	3.66%	Beta	-2.20	Target Price	32.43
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	17.03%	Rel Volume	0.81	Prev Close	18.24
Employees	130	LT Debt/Eq	0.00	Earnings	Aug 12 BMO	SMA200	76.21%	Avg Volume	191.28K	Price	19.07
IPO	Sep 13, 2024	Option/Short	Yes / No	EPS/Sales Surpr.	-20.42% -100.00%	Trades		Volume	154,233	Change	4.52%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-20-25	Initiated	Wedbush	Outperform	$35
Feb-04-25	Initiated	Wolfe Research	Outperform	$19
Dec-16-24	Initiated	H.C. Wainwright	Buy	$30
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$34
Oct-08-24	Initiated	Morgan Stanley	Overweight	$40
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$45
Oct-08-24	Initiated	Citigroup	Buy	$27

Sep-02-25 07:05AM	Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million (GlobeNewswire) +9.50%
Aug-26-25 07:05AM	Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-12-25 07:05AM	Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +6.68%
Jun-20-25 04:15PM	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-13-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -8.75%
04:00AM	Loading…
Jun-02-25 04:00AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) +5.67%
May-29-25 07:05AM	Zenas BioPharma to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +8.34%
May-28-25 09:31AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) -12.59%
May-16-25 05:45AM	Investors in Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +7.49%
May-15-25 07:05AM	Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +12.21%
May-06-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -19.71%
May-02-25 05:45AM	Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire)
Apr-29-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +12.56%
Apr-22-25 10:37AM	Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses (GlobeNewswire)
Apr-21-25 12:33PM	Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses (GlobeNewswire) +9.30%
04:20PM	Loading…
Apr-17-25 04:20PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.08%
Apr-07-25 03:08PM	Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst (Seeking Alpha)
07:05AM	Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Mar-20-25 02:54PM	Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress (Benzinga)
11:41AM	Zenas Bio rises as Wedbush launches with Outperform on lead asset (SeekingAlpha)
Mar-17-25 07:05AM	Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer (GlobeNewswire)
Feb-05-25 07:05AM	Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases (GlobeNewswire)
Jan-28-25 08:00AM	Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-17-24 06:25AM	Zenas BioPharma initiated with a Buy at H.C. Wainwright (TipRanks) +8.10%
Dec-12-24 07:35AM	Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley (TipRanks)
Nov-12-24 07:10AM	Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
07:05AM	Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
Nov-07-24 07:05AM	Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks) +7.63%
Sep-19-24 04:15PM	Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering (GlobeNewswire) +8.45%
04:09PM	Loading…
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 10:37PM	Zenas BioPharma Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MOULDER LEON O JR	Chief Executive Officer	Feb 18 '25	Buy	6.67	25,000	166,750	266,155	Feb 19 04:01 PM
Xiao Ting	Director	Feb 07 '25	Buy	7.76	10,000	77,600	47,000	Feb 11 04:20 PM
MOULDER LEON O JR	Chief Executive Officer	Dec 04 '24	Buy	9.98	45,000	449,100	241,155	Dec 04 09:03 PM
MOULDER LEON O JR	Chief Executive Officer	Dec 03 '24	Buy	10.76	25,000	269,000	196,155	Dec 04 09:03 PM
MOULDER LEON O JR	Chief Executive Officer	Nov 18 '24	Buy	15.00	7,500	112,500	168,655	Nov 20 05:20 PM
MOULDER LEON O JR	Chief Executive Officer	Nov 19 '24	Buy	14.57	2,500	36,425	171,155	Nov 20 05:20 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 18 '24	Buy	17.91	10,000	179,100	1,662,039	Sep 20 06:34 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 20 '24	Buy	18.45	5,000	92,270	1,672,039	Sep 20 06:34 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 19 '24	Buy	17.89	5,000	89,450	1,667,039	Sep 20 06:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZBIO

Zenas Biopharma Inc

Upgrade your FINVIZ experience